Osamu Maehara

Affiliation and department：

Research field (1)： Tumor biology

Research theme for competitive and other funds (4)：

2022 - 2025 食道扁平上皮癌がん幹細胞における免疫逃避機構の解明
2020 - 2023 肝細胞癌幹細胞におけるレンバチニブ耐性機構の解明
2017 - 2019 メトホルミンによるがん幹細胞マーカーCD133発現抑制機構の解明
2015 - 2018 FGFR inhibitors eliminate cancer stem-like cells in esophageal squamous cell carcinoma

Papers (54)：

Naohiro Yasuura, Goki Suda, Masatsugu Ohara, Akimitsu Meno, Takuya Sho, Risako Kohya, Takashi Sasaki, Tomoka Yoda, Sonoe Yoshida, Qingjie Fu, et al. Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC. Alimentary pharmacology & therapeutics. 2024
Risako Kohya, Goki Suda, Masatsugu Ohara, Takashi Sasaki, Tomoka Yoda, Naofumi Sakurai, Sonoe Yoshida, Qingjie Fu, Zijian Yang, Shunichi Hosoda, et al. Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma. Cancers. 2023. 15. 12
Takashi Sasaki, Goki Suda, Masatsugu Ohara, Shunichi Hosoda, Naoki Kawagishi, Risako Kohya, Tomoka Yoda, Osamu Maehara, Shunsuke Ohnishi, Sonoe Yoshida, et al. Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan. Hepatology research : the official journal of the Japan Society of Hepatology. 2023
Shunichi Hosoda, Goki Suda, Takuya Sho, Koji Ogawa, Megumi Kimura, Zijian Yang, Sonoe Yoshida, Akinori Kubo, Yoshimasa Tokuchi, Takashi Kitagataya, et al. Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment. Liver cancer. 2023. 12. 2. 156-170
Yoshimasa Tokuchi, Goki Suda, Naoki Kawagishi, Masatsugu Ohara, Risako Kohya, Takashi Sasaki, Tomoka Yoda, Osamu Maehara, Shunsuke Ohnishi, Akinori Kubo, et al. Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight. Hepatology research : the official journal of the Japan Society of Hepatology. 2023. 53. 7. 595-606

ｍore...

MISC (3)：

大原正嗣, 大西俊介, 山本幸司, 付慶傑, 前原経, 須田剛生, 坂本直哉. 羊膜間葉系幹細胞由来細胞外小胞の慢性肝障害モデルに対する抗炎症・抗線維化効果. 日本再生医療学会総会(Web). 2019. 18th
N. Kawagishi, G. Suda, M. Onozawa, M. Kimura, O. Maehara, M. Ohara, T. Izumi, M. Umemura, J. Ito, M. Nakai, et al. Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C. JOURNAL OF HEPATOLOGY. 2017. 66. 1. S725-S726
佐藤史幸, 夏井坂光輝, 前原経, 浅野彩華, 久保田良政, 出水孝章, 梅村真知子, 伊藤淳, 常松聖司, 中井正人, et al. 肝細胞癌におけるKLF5による癌幹細胞制御機構. 肝臓. 2015. 56. Suppl.3. A1002-A1002

Lectures and oral presentations (4)：

羊膜間葉系幹細胞由来細胞外小胞の慢性肝障害モデルに対する抗炎症・抗線維化効果
(日本再生医療学会総会(Web) 2019)
食道扁平上皮がん(ESCC)がん幹細胞に対するFGFR阻害剤の効果
(再生医療 2016)
肝細胞癌におけるKLF5による癌幹細胞制御機構
(肝臓 2015)
KLF5 Promotes Tumorigenicity of Hepatocellular Carcinoma by Upregulation of Cancer Stem-Like Cells
(GASTROENTEROLOGY 2015)

Education (2)：

2014 - 2018 Hokkaido University Graduate School of Life Science
2008 - 2014 Hokkaido University Faculty of Pharmaceutical Sciences Department of Pharmacy

Professional career (1)：

博士 (臨床薬学) (北海道大学)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page